Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

229118

registered interest
date	23/03/2015
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	North Korea
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, with reference to the report of the United Nations Panel of Experts on the DPRK, published on 23 February 2015, what steps he has taken to prevent North Korean diplomats, officials and trade representatives from engaging in illicit activities.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228700
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>We are concerned by the evidence in the Panel of Experts’ report that diplomats, officials and trade representatives of the Democratic People’s Republic of Korea (DPRK) continue to play key roles in facilitating trade of prohibited items. The DPRK’s global proliferation activity not only provides revenue for its nuclear and ballistic missile programmes, but also threatens global security. The UK is committed to upholding UN Security Council Resolutions on the DPRK which encourage Member States to exercise vigilance over all activities of DPRK diplomatic personnel.</p><p> </p><p>The UK supports the Panel of Experts by raising awareness of the potential for the DPRK to misuse its diplomatic premises for proliferation and procurement purposes, and by encouraging UN member states to identify any illicit activity. In March 2015, the Foreign and Commonwealth Office hosted a visit by the Coordinator of the UN Panel of Experts to the UK, during which the issues raised by the Panel’s report were discussed.</p> answering member constituency East Devon answering member printed Mr Hugo Swire question first answered 26/03/2015 09:24:02 answering member 1408 label Biography information for Lord Swire
tabling member	3958 label Biography information for Fiona Bruce

229119

registered interest
date	23/03/2015
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	North Korea
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, with reference to the comments of 20 March 2015 by the North Korea Ambassador to the UK, what assessment she has made of the safety of refugees from North Korea.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228701
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The Government has noted the remarks made by the Ambassador. All asylum and human rights claims including those made by North Koreans are, and will continue to be, considered on their individual merits in accordance with our obligations under the 1951 Refugee Convention and against the background of the latest available country information and caselaw.</p><p> </p> answering member constituency Old Bexley and Sidcup answering member printed James Brokenshire question first answered 26/03/2015 10:23:11 answering member 1530 label Biography information for James Brokenshire
tabling member	3958 label Biography information for Fiona Bruce

229120

registered interest
date	23/03/2015
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	North Korea
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, with reference to the comments of 20 March 2015 by the North Korean Ambassador to the UK, what assessment he has made of the North Korea's preparedness for nuclear war.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228702
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>We remain deeply concerned by the Democratic People’s Republic of Korea’s (DPRK) development of its nuclear and ballistic missile programmes. The DPRK has stated its intention to develop and deploy nuclear weapons and has conducted nuclear and ballistic missile tests, in violation of UN Security Council Resolutions. While the DPRK has made frequent public statements regarding its nuclear capabilities, it provides little substantive information on the precise nature of those capabilities.</p><p> </p><p>We have made very clear that the DPRK must comply with its obligations under all relevant UN Security Council Resolutions. This includes not conducting further nuclear tests, or tests involving ballistic missile technologies. Any further nuclear test will be met by a robust international response.</p> answering member constituency East Devon answering member printed Mr Hugo Swire question first answered 26/03/2015 09:28:58 answering member 1408 label Biography information for Lord Swire
tabling member	3958 label Biography information for Fiona Bruce

229159

registered interest
date	23/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answers of 2 December 2014 to Question HL2907 and 17 March 2015 to Question HL5319 and the Written Statement of 24 November 2010, Official Report, columns WS101-2, on Questions for Written Answer: Correction, how many incidents of hospitalisation due to ovarian hyperstimulation syndrome (OHSS) have been reported to the Human Fertilisation and Embryology Authority (HFEA); what steps the HFEA takes to ensure that any suspected serious adverse reactions are reported to the licensing authority in accordance with the Human Medicines Regulations 2012; what steps the HFEA takes in cases of failure to report any such incidents to the Medicines and Healthcare Products Regulatory Agency; and whether he is satisfied that the HFEA is doing enough to protect patients from OHSS.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228699
answer	answer is ministerial correction date of answer 26/03/2015 answer text <p>The information the Human Fertilisation and Embryology Authority (HFEA) holds on number of incidents of hospitalisation due to ovarian hyperstimulation syndrome (OHSS), that have been reported to the Authority, is set out in the written answer provided to the then hon. Member for Heywood and Middleton on 24 June 2014, <em>Official Report,</em> columns 156-157W (UIN 201565).</p><p> </p><p> </p><p> </p><p>The HFEA has advised that the responsibility for reporting adverse reactions in accordance with the Human Medicines Regulations 2012 rests with clinics and the treating clinician. Should the HFEA be made aware of information relevant to the regulatory functions of the Medicines and Healthcare products Regulatory Agency, this information would be shared between the two organisations.</p><p> </p><p> </p><p> </p><p>The Department is satisfied that the Authority is fulfilling its statutory duties as set out in the Human Fertilisation and Embryology Act 1990, as amended.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 26/03/2015 11:28:01 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

228582

registered interest
date	19/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether NHS England will remain the sole budget-holder for prescribed specialised services in 2016-17.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228424
answer	answer is ministerial correction date of answer 24/03/2015 answer text <p>NHS England is the accountable commissioner and budget holder for all specialised services as set out in the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, with the Manual for prescribed specialised services providing further detail.</p><p> </p><p> </p><p> </p><p>NHS England has achieved significant progress in developing a set of nationally consistent service standards and commissioning policies, which ensure equity of access to high quality services across the board. Those standards and policies will continue to apply for those specialised services which are to be collaboratively commissioned by NHS England and clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>NHS England has clarified that where there are collaboratively commissioned services, NHS England will retain the full financial risk for these services for 2015/16. NHS England has advised that there will be further work conducted over the next year to advise the range of specialised services for which NHS England should remain the accountable commissioner and budget holder for 2016/17 and future years.</p><p> </p><p> </p><p> </p><p>Copies of the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012 and the Manual for prescribed specialised services are attached.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison attachment 1 file name Resposibilities and Standing Rules Regulations.pdf title NHS Commissioning Board & CCG Regulations 2012 2 file name NHS commissioning Board - Manual.pdf title Manual for prescribed special services question first answered 24/03/2015 17:39:48 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

228308

registered interest
date	18/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the contribution of the Parliamentary Under-Secretary of State for Health of 31 October 2012, Official Report, column 93WH, what his Department's definition of viability is for the gestational time limit for abortion.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	228203
answer	answer is ministerial correction date of answer 23/03/2015 answer text <p>In 1990, Parliament decided that the legal time limit for most abortions should be 24 weeks.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 23/03/2015 16:41:44 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

227861

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the implications for his policies of the assertion that there is some evidence that emergency hormonal contraception schemes are associated with higher teenage conception rates, in the article, The impact of emergency birth control on teen pregnancy and sexually transmitted diseases, by Professor David Paton of the Nottingham University Business School, published in the Journal of Health Economics in March 2011.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	227979
answer	answer is ministerial correction date of answer 20/03/2015 answer text <p>No assessment has been made of the publication in question.</p><p> </p><p> </p><p> </p><p>In 2013, the under 18 conception rate was 24.3 per 1,000 women aged 15-17, a fall of 12.3% from 2012 and the lowest rate for 40 years. No research has been commissioned into the links between use of contraception and rates of STIs in young people.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 227926 question first answered 20/03/2015 14:38:43 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

227866

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department has conducted or commissioned research into whether there is a link between the promotion of hormonal contraceptives in teenage pregnancy reduction schemes and levels of sexually transmitted infections in young people.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	227926
answer	answer is ministerial correction date of answer 20/03/2015 answer text <p>No assessment has been made of the publication in question.</p><p> </p><p> </p><p> </p><p>In 2013, the under 18 conception rate was 24.3 per 1,000 women aged 15-17, a fall of 12.3% from 2012 and the lowest rate for 40 years. No research has been commissioned into the links between use of contraception and rates of STIs in young people.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 227979 question first answered 20/03/2015 14:38:43 answering member 3918 label Biography information for Jane Ellison
tabling member	3958 label Biography information for Fiona Bruce

227887

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what arrangements are in place to monitor side-effects resulting from women's use of emergency hormonal contraception.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	227923
answer	answer is ministerial correction date of answer 20/03/2015 answer text <p>In the United Kingdom emergency hormonal contraception is available from pharmacies, with or without prescription as Levonelle/Levonelle One Step (levonorgestrel-containing products) and as ellaOne (containing ulipristal acetate). Product licences were granted following advice from the UK’s Commission on Human Medicines (formerly the Committee on Safety of Medicines) and the European Union’s Committee for Medicinal Products for Human Use respectively, based on a review of all the available evidence for safety, efficacy and quality.</p><p> </p><p> </p><p> </p><p>As with all other licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of emergency hormonal contraception under close review using a number of data sources. These include reports of suspected adverse drug reactions, provided by health professionals and patients through the ‘Yellow Card scheme’ , periodic safety update reports, published medical literature and the results of any new clinical trials or epidemiological studies. Any of these data sources may include information on single use, repeat use or suspected long-term adverse effects.</p><p> </p><p> </p><p> </p><p>No clinical studies of the long term safety of emergency hormonal contraception have been conducted. However, levonorgestrel has been available worldwide since the 1980s. Since then millions of women have used it for emergency contraception and no major safety concerns have arisen. For the more recently authorised ellaOne a pregnancy registry to collect further information on the safety of ellaOne has been established and could yield long-term safety data in the future. Clinical trial data show that the safety of repeated administration of ellaOne is comparable with that of a single dose. Information provided for health professionals and women advises that emergency hormonal contraception should be used as an occasional method and encourages repeat users to seek advice on regular contraception.</p><p> </p><p> </p><p> </p><p>As with all marketed medicines, the MHRA will continue to monitor the use of emergency hormonal contraception.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 227924 227925 question first answered 20/03/2015 13:50:42 answering member 4020 label Biography information for George Freeman
tabling member	3958 label Biography information for Fiona Bruce

227888

registered interest
date	17/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what research his Department has considered on the long-term effects of repeat use of emergency hormonal contraception on women's health.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	227924
answer	answer is ministerial correction date of answer 20/03/2015 answer text <p>In the United Kingdom emergency hormonal contraception is available from pharmacies, with or without prescription as Levonelle/Levonelle One Step (levonorgestrel-containing products) and as ellaOne (containing ulipristal acetate). Product licences were granted following advice from the UK’s Commission on Human Medicines (formerly the Committee on Safety of Medicines) and the European Union’s Committee for Medicinal Products for Human Use respectively, based on a review of all the available evidence for safety, efficacy and quality.</p><p> </p><p> </p><p> </p><p>As with all other licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of emergency hormonal contraception under close review using a number of data sources. These include reports of suspected adverse drug reactions, provided by health professionals and patients through the ‘Yellow Card scheme’ , periodic safety update reports, published medical literature and the results of any new clinical trials or epidemiological studies. Any of these data sources may include information on single use, repeat use or suspected long-term adverse effects.</p><p> </p><p> </p><p> </p><p>No clinical studies of the long term safety of emergency hormonal contraception have been conducted. However, levonorgestrel has been available worldwide since the 1980s. Since then millions of women have used it for emergency contraception and no major safety concerns have arisen. For the more recently authorised ellaOne a pregnancy registry to collect further information on the safety of ellaOne has been established and could yield long-term safety data in the future. Clinical trial data show that the safety of repeated administration of ellaOne is comparable with that of a single dose. Information provided for health professionals and women advises that emergency hormonal contraception should be used as an occasional method and encourages repeat users to seek advice on regular contraception.</p><p> </p><p> </p><p> </p><p>As with all marketed medicines, the MHRA will continue to monitor the use of emergency hormonal contraception.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 227923 227925 question first answered 20/03/2015 13:50:42 answering member 4020 label Biography information for George Freeman
tabling member	3958 label Biography information for Fiona Bruce